Prospera Financial Services Inc, an institutional investor, has recently disclosed its acquisition of a new position in TG Therapeutics (TGTX), according to the Securities and Exchange Commission. The purchase consisted of 18,650 shares of the biopharmaceutical company’s stock, valued at approximately $221,000. This move indicates growing interest from institutional investors and hedge funds in TG Therapeutics.
WJ Interests LLC, another institutional investor, also entered the scene by purchasing a stake in TG Therapeutics during the fourth quarter, with a value of about $35,000. Additionally, Allspring Global Investments Holdings LLC increased its position in the company by 517.1% in the third quarter, now owning 6,603 shares worth $39,000. Great West Life Assurance Co. Can and Macquarie Group Ltd. joined the list of investors, buying stakes in TG Therapeutics worth approximately $40,000 and $43,000, respectively. Metropolitan Life Insurance Co NY also raised its position by 28.7% during the third quarter, holding 8,029 shares valued at $48,000. In total, institutional investors and hedge funds now own approximately 68.06% of the company’s stock.
TGTX Stock Growth
TG Therapeutics’ stock experienced a 0.8% increase, opening at $31.15 on Tuesday. The company currently boasts a market capitalization of $4.65 billion. TG Therapeutics has a current financial short ratio of 5.94 each. Over the past twelve months, the stock has ranged from a low of $3.48 to a high of $35.67. Notably, the stock’s 50-day moving average stands at $21.07, while its two-hundred-day moving average rests at $14.92.
On May 1st, TG Therapeutics released its quarterly earnings report, surpassing analysts’ expectations. Despite a negative net margin of 1,966.56% and a negative return on equity of 175.51%, TG Therapeutics generated $7.80 million in revenue for the quarter, representing a remarkable 290.0% increase compared to the previous year. Analysts anticipate that TG Therapeutics, Inc. will post a loss per share of -1 for the current fiscal year.
The recent acquisition of TG Therapeutics’ stock by Prospera Financial Services Inc and other institutional investors signifies a growing interest in the company and its potential for future growth. With positive quarterly earnings results and a solid revenue increase, TG Therapeutics continues to attract attention from the investment community.
Investors Overview
TGTX stock has seen a 0.8% rise as institutional investors like Prospera Financial Services Inc and hedge funds show increased interest in TG Therapeutics. The recent acquisition of 18,650 shares by Prospera Financial Services Inc, valued at approximately $221,000, is an indicator of growing investment activity. Other institutions such as WJ Interests LLC, Allspring Global Investments Holdings LLC, Great West Life Assurance Co. Can, Macquarie Group Ltd., and Metropolitan Life Insurance Co NY have also added stakes in the company.
As a result, the TGTX stock price opened at $31.15 on Tuesday, reflecting the positive market sentiment. With a market capitalization of $4.65 billion and a beta of 2.08, TG Therapeutics’ stock has shown resilience in the face of market fluctuations.
Investors are closely monitoring TG Therapeutics, and platforms like StockTwits have seen increased discussions around the company’s stock. The acquisition of TG Therapeutics’ shares by Prospera Financial Services Inc and other institutional investors has sparked interest and speculation among traders.
TGTX stock forecast 2025
Looking ahead, there is considerable TGTX stock forecast optimism. Analysts expect TG Therapeutics to continue its growth trajectory, with revenue for the most recent quarter reaching $7.80 million, a remarkable 290.0% increase year-over-year. The company’s ability to surpass earnings expectations, with an earnings per share of ($0.28) compared to the consensus estimate of ($0.36), has further bolstered confidence in its future prospects.
While TG Therapeutics has faced challenges, including a negative net margin of 1,966.56% and a negative return on equity of 175.51%, the company’s recent performance indicates promising developments. As the biopharmaceutical industry evolves, TG Therapeutics remains committed to advancing its pipeline of innovative therapies.
Amidst these positive indicators, investors are eager for the TGTX stock forecast 2025. The company’s strong financial performance, growing institutional interest, and positive market sentiment all contribute to a positive outlook for TG Therapeutics over the coming years. However, it’s important to note that investment forecasts are subject to various factors and market conditions that can impact Stock performance.
As TG Therapeutics continues to make strides in its research and development efforts, investors and analysts will closely follow its progress. The acquisition of TG Therapeutics’ shares by Prospera Financial Services Inc and other institutional investors underscores the belief in the company’s long-term growth potential.
TGTX Stock Analysis & Forecast
According to 10 analysts’ forecasts, the average target price for TG Therapeutics Inc over the next 12 months is USD 28.25. The consensus among analysts is to “Buy” the stock. However, Stock Target Advisor’s own analysis of TG Therapeutics Inc indicates a slightly bearish outlook, based on 3 positive signals and 4 negative signals. As of the last closing, the stock price of TG Therapeutics Inc stood at USD 31.15. Over the past week, the stock price has decreased by -5.89%, while it has experienced significant gains of +53.30% over the past month and an impressive +379.23% over the last year.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.
